Published in N Engl J Med on January 06, 2005
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia | NCT01082588
Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement (STARC) | NCT05076019
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet (2011) 4.23
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Infection, inflammation, height, and longevity. Proc Natl Acad Sci U S A (2005) 3.17
Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med (2014) 3.09
Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 3.09
Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry (2008) 2.82
Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet (2005) 2.71
Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA (2013) 2.68
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax (2006) 2.38
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J (2015) 2.25
Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg (2006) 2.14
Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med (2011) 2.08
Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ (2005) 1.90
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis (2014) 1.86
Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int (2006) 1.83
Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med (2006) 1.81
Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells. Arterioscler Thromb Vasc Biol (2013) 1.78
Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry (2008) 1.73
Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J (2010) 1.67
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J (2011) 1.66
Is depression an inflammatory disorder? Curr Psychiatry Rep (2011) 1.60
The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J (2014) 1.53
The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med (2008) 1.51
Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertens Res (2011) 1.50
Potential therapeutic role for statins in respiratory disease. Thorax (2006) 1.49
Atherosclerosis, cholesterol, nutrition, and statins--a critical review. Ger Med Sci (2007) 1.49
Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov (2011) 1.48
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes (2011) 1.47
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther (2007) 1.41
Innate and adaptive immunity in atherosclerosis. Semin Immunopathol (2009) 1.40
Chocolate and prevention of cardiovascular disease: a systematic review. Nutr Metab (Lond) (2006) 1.40
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
Inflammation and infection do not promote arterial aging and cardiovascular disease risk factors among lean horticulturalists. PLoS One (2009) 1.38
C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol (2005) 1.37
Association of statin use with cognitive decline in elderly African Americans. Neurology (2007) 1.34
Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation (2011) 1.31
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation (2010) 1.29
ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med (2006) 1.27
Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag (2006) 1.23
Biomarkers in acute myocardial infarction. BMC Med (2010) 1.22
From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res (2016) 1.22
C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol (2011) 1.21
Life course socioeconomic position is associated with inflammatory markers: the Framingham Offspring Study. Soc Sci Med (2010) 1.21
The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med (2008) 1.21
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res (2016) 1.20
Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci U S A (2007) 1.20
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol (2011) 1.19
Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation (2008) 1.19
Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis (2008) 1.19
Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat Rev Cardiol (2009) 1.17
Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost (2009) 1.16
Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res (2008) 1.16
Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag (2008) 1.16
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr (2007) 1.14
Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manag (2006) 1.13
Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol (2013) 1.12
Innate immune cells in liver inflammation. Mediators Inflamm (2012) 1.11
Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol (2009) 1.11
C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail (2007) 1.10
Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care (2008) 1.09
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail (2009) 1.09
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation (2009) 1.08
Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis (2015) 1.08
Statins for atherosclerosis--as good as it gets? N Engl J Med (2005) 1.08
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1beta and C-reactive protein. Hum Genet (2008) 1.06
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol (2009) 1.04
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses (2010) 1.04
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring) (2013) 1.04
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart (2007) 1.04
Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med (2008) 1.01
Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci (2012) 1.01
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes (2013) 1.01
Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr (2007) 1.00
High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum (2008) 1.00
Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol (2009) 0.99
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. Br J Pharmacol (2005) 0.99
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis (2013) 0.99
The influence of anti-infective periodontal treatment on C-reactive protein: a systematic review and meta-analysis of randomized controlled trials. PLoS One (2013) 0.99
Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis. Cell Adh Migr (2007) 0.98
Gender differences in the association between C-reactive protein, lung function impairment, and COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.98
Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis (2007) 0.97
Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk. Brain Behav Immun (2007) 0.97
Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag (2006) 0.97
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc (2013) 0.96
Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol (2012) 0.96
Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol (2006) 0.95
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int (2016) 0.95
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep (2013) 0.95
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation (2004) 4.58
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Association between C-reactive protein and age-related macular degeneration. JAMA (2004) 4.16
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09
Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA (2004) 4.04
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation (2005) 3.85
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71